These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8110584)

  • 1. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man.
    Wappler F; Roewer N; Lenzen C; Köchling A; Scholz J; Steinfath M; Schulte am Esch J
    Br J Anaesth; 1994 Feb; 72(2):240-2. PubMed ID: 8110584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High purity ryanodine for in vitro diagnosis of malignant hyperthermia].
    Wappler F; Roewer N; Lenzen C; Scholz J; Steinfath M; Rumberger R; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1993 Nov; 28(7):427-31. PubMed ID: 8297948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles.
    Wappler F; Roewer N; Köchling A; Scholz J; Steinfath M; Schulte am Esch J
    Anesth Analg; 1996 Jun; 82(6):1230-6. PubMed ID: 8638796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients.
    Lenzen C; Roewer N; Wappler F; Scholz J; Kahl J; Blank M; Rumberger E; Schulte am Esch J
    Br J Anaesth; 1993 Aug; 71(2):242-6. PubMed ID: 8123400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility].
    Lenzen C; Roewer N; Scholz J; Rumberger E; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):459-63. PubMed ID: 1786306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Fiege M; Wappler F; Scholz J; Weisshorn R; von Richthofen V; Schulte am Esch J
    J Clin Anesth; 2000 Mar; 12(2):123-8. PubMed ID: 10818326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
    Ording H; Glahn K; Gardi T; Fagerlund T; Bendixen D
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):967-72. PubMed ID: 9311392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia].
    Wappler F; Roewer N; Köchling A; Scholz J; Steinfath M; Rumberger E; Löscher W; Schulte am Esch J
    Anaesthesist; 1995 Aug; 44(8):538-44. PubMed ID: 7573901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is a presymptomatic malignant hyperthermia in-vitro diagnosis with 4-chloro-3-ethyl phenol possible? A study using porcine skeletal preparations].
    Gerbershagen MU; Wappler F; Fiege M; Weisshorn R; Kolodzie K; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2004 Feb; 39(2):81-6. PubMed ID: 14767797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
    Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
    J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.